Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration.
Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration.
复制标题
DOI：
10.1186/s12886-017-0586-0
复制
发表时间：
2017-10-10
影响因子：
2
通讯作者：
Vinker S
中科院分区：
文献类型：
--
作者：
Hanhart J;Comaneshter DS;Freier Dror Y;Vinker S
本研究的目的是分析贝伐单抗治疗湿性AMD患者的死亡率。我们在2008年9月至2014年10月期间接受玻璃体内注射贝伐单抗作为渗出性AMD唯一治疗的患者（n = 5385）与年龄和性别匹配的对照组（n = 10，756）之间进行了一项回顾性病例对照研究。对纳入研究的所有个体进行了社会人口学数据和合并症审查。使用校正的考克斯回归，使用相关的校正变量进行生存分析。在随访期间（最长：73个月），贝伐单抗治疗组有1063人（19.7%）死亡，对照组有1298人（12.1%）死亡（P <0.001）。经校正的考克斯生存回归分析后，两组死亡率差异显著，比值比= 1.69，（95% CI. 1.54-1.84），P < .001。我们发现，与相同年龄和性别的非湿性AMD患者相比，贝伐单抗治疗的湿性AMD患者的长期死亡率增加。
The aim of this study is to analyze mortality in patients treated with bevacizumab for wet AMD. We conducted a retrospective case-control study between patients who received intravitreal injections of bevacizumab as the sole treatment for exudative AMD between September 2008 and October 2014 (n = 5385) and age and gender matched controls (n = 10,756). All individuals included in the study were reviewed for sociodemographic data and comorbidities. Survival analysis was performed using adjusted Cox regression, using relevant adjusted variables. During follow-up (maximum: 73 months), 1063 (19.7%) individuals after bevacizumab died compared with 1298 (12.1%) in the control group (P < .001). After adjusted Cox survival regression, mortality differed significantly between the groups, Odds ratio = 1.69, (95% C.I. 1.54–1.84), P < .001. We found an increased long-term mortality in individuals with wet AMD treated with bevacizumab compared to a same age and gender group without wet AMD.
登录
查看更多内容
影响因子：
13.7
作者：
Solomon SD;Lindsley KB;Krzystolik MG;Vedula SS;Hawkins BS
通讯作者：
Hawkins BS
影响因子：
6.3
作者：
Pedula KL;Coleman AL;Yu F;Cauley JA;Ensrud KE;Hochberg MC;Fink HA;Hillier TA;Study of Osteoporotic Fractures Research Group
通讯作者：
Study of Osteoporotic Fractures Research Group
影响因子：
8.3
作者：
Ikram MK;Mitchell P;Klein R;Sharrett AR;Couper DJ;Wong TY
通讯作者：
Wong TY
DOI：
10.1177/1740774512438980
发表时间：
2012-06
期刊：
Clinical trials (London, England)
影响因子：
--
作者：
Grinnon ST;Miller K;Marler JR;Lu Y;Stout A;Odenkirchen J;Kunitz S
通讯作者：
Kunitz S
影响因子：
13.7
作者：
Michels, S;Rosenfeld, PJ;Venkatraman, AS
通讯作者：
Venkatraman, AS